Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Growth 2023-2029

Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Growth 2023-2029

Chemotherapy-induced nausea and vomiting (CINV) is a common side-effect of many cancer treatments. Nausea and vomiting are two of the most feared cancer treatment-related side effects for cancer patients and their families. In 1983, Coates et al. found that patients receiving chemotherapy ranked nausea and vomiting as the first and second most severe side effects, respectively. Up to 20% of patients receiving highly emetogenic agents in this era postponed, or even refused, potentially curative treatments. Since the 1990s, several novel classes of antiemetics have been developed and commercialized, becoming a nearly universal standard in chemotherapy regimens, and helping to better manage these symptoms in a large portion of patients. Efficient mediation of these unpleasant and sometimes crippling symptoms results in increased quality of life for the patient, and better overall health of the patient, and, due to better patient tolerance, more effective treatment cycles.
Affecting 70-80% of patients undergoing chemotherapy, chemotherapy-induced nausea and vomiting (CINV) is one of chemotherapy's most debilitating side effects, often attributed as a leading cause of premature discontinuation of cancer treatment.
LPI (LP Information)' newest research report, the “Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Industry Forecast” looks at past sales and reviews total world Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs sales for 2023 through 2029. With Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs industry.
This Insight Report provides a comprehensive analysis of the global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs.
The global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs market size is projected to grow from US$ 2311.6 million in 2022 to US$ 2056 million in 2029; it is expected to grow at a CAGR of 2056 from 2023 to 2029.
Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs key players include Haisco, Merck, Mundipharma, Qilu Pharma, Heron Therapeutics, Teva, etc. Global top six manufacturers hold a share about 30%.
North America is the largest market, with a share about 35%, followed by Europe and Asia-Pacific, both have a share about 60 percent.
In terms of product, 5-HT3 Inhibitors is the largest segment, with a share over 70%. And in terms of application, the largest application is Acute CINV, followed by Delayed CINV and Breakthrough CINV.
This report presents a comprehensive overview, market shares, and growth opportunities of Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
5-HT3 Inhibitors
NK1 Inhibitors
Others
Segmentation by application
Acute CINV
Delayed CINV
Breakthrough CINV
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Heron Therapeutics
Merck
Eisai
Mundipharma
Qilu Pharma
Teva
Novartis
Roche
Mylan
Baxter
GSK
Helsinn
Southwest Pharma
Haisco
Sun Pharma

Key Questions Addressed in this Report
What is the 10-year outlook for the global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs market?
What factors are driving Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs market opportunities vary by end market size?
How does Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.